Potential biomarkers for immunotherapy in non-small-cell lung cancer

被引：13

作者：

Wang, Xing ^{[1
]}

Qiao, Ziyun ^{[1
]}

Aramini, Beatrice ^{[2
]}

Lin, Dong ^{[1
]}

Li, Xiaolong ^{[1
]}

Fan, Jiang ^{[1
]}

机构：

[1] Shanghai Gen Hosp, Dept Thorac Surg, Shanghai, Peoples R China

[2] Univ Bologna, GB Morgagni L Pierantoni Hosp, Dept Expt Diagnost & Specialty Med DIMES Alma Mate, Div Thorac Surg, Forli, Italy

来源：

CANCER AND METASTASIS REVIEWS | 2023年 / 42卷 / 03期

基金：

中国国家自然科学基金;

关键词：

Non-small-cell lung cancer; Immune checkpoint inhibitors; Biomarker; CIRCULATING TUMOR DNA; METASTATIC UROTHELIAL CARCINOMA; RESIDUAL DISEASE MRD; PD-L1; EXPRESSION; OPEN-LABEL; MUTATIONAL BURDEN; METHYLATION MARKERS; 1ST-LINE TREATMENT; PREDICTS RESPONSE; PROGNOSTIC VALUE;

D O I：

10.1007/s10555-022-10074-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

For individuals with advanced or metastatic non-small cell lung cancer (NSCLC), the primary treatment is platinum-based doublet chemotherapy. Immune checkpoint inhibitors (ICIs), primarily PD-1/PD-L1 and CTLA-4, have been found to be effective in patients with NSCLC who have no EGFR/ALK mutations. Furthermore, ICIs are considered a standard therapy. The quantity of fresh immunogenic antigens discovered by cytotoxic T cells was measured by PD-L1 expression and tumor mutational burden (TMB), which were the first biomarkers assessed in clinical trials. However, immunotherapy did not have response efficacy markers similar to targeted therapy, highlighting the significance of newly developed biomarkers. This investigation aims to review the research on immunotherapy for NSCLC, focusing primarily on the impact of biomarkers on efficacy prediction to determine whether biomarkers may be utilized to evaluate the effectiveness of immunotherapy.

引用

页码：661 / 675

页数：15

共 153 条

[11] Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer The PROLUNG Phase 2 Randomized Clinical Trial [J].

Arrieta, Oscar ;

Barron, Feliciano ;

Ramirez-Tirado, Laura Alejandra ;

Zatarain-Barron, Zyanya Lucia ;

Cardona, Andres F. ;

Diaz-Garcia, Diego ;

Yamamoto Ramos, Masao ;

Mota-Vega, Beatriz ;

Carmona, Amir ;

Peralta alvarez, Marco Polo ;

Bautista, Yolanda ;

Aldaco, Fernando ;

Gerson, Raquel ;

Rolfo, Christian ;

Rosell, Rafael .

JAMA ONCOLOGY, 2020, 6 (06) :856-864

[12] SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer [J].

Balgkouranidou, Ioanna ;

Chimonidou, Maria ;

Milaki, Georgia ;

Tsaroucha, Emily ;

Kakolyris, Stylianos ;

Georgoulias, Vasilis ;

Lianidou, Evi .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2016, 54 (08) :1385-1393

[13] Epigenetic Determinants of Cancer [J].

Baylin, Stephen B. ;

Jones, Peter A. .

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2016, 8 (09)

[14] A decade of exploring the cancer epigenome - biological and translational implications [J].

Baylin, Stephen B. ;

Jones, Peter A. .

NATURE REVIEWS CANCER, 2011, 11 (10) :726-734

[15] Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer [J].

Besse, Benjamin ;

Garrido, Pilar ;

Cortot, Alexis B. ;

Johnson, Melissa ;

Murakami, Haruyasu ;

Gazzah, Anas ;

Gil, Maciej ;

Bennouna, Jaafar .

LUNG CANCER, 2020, 142 :63-69

[16]

Board RE, 2007, BIOMARK INSIGHTS, V2, P307

[17] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[18] DNA methylation markers and early recurrence in stage I lung cancer [J].

Brock, Malcolm V. ;

Hooker, Craig M. ;

Ota-Machida, Emi ;

Han, Yu ;

Guo, Mingzhou ;

Ames, Stephen ;

Gloeckner, Sabine ;

Piantadosi, Steven ;

Gabrielson, Edward ;

Pridham, Genevieve ;

Pelosky, Kristen ;

Belinsky, Steven A. ;

Yang, Stephen C. ;

Baylin, Stephen B. ;

Herman, James G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) :1118-1128

[19] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population [J].

Brzezianska, Ewa ;

Karbownik, Malgorzata ;

Migdalska-Sek, Monika ;

Pastuszak-Lewandoska, Dorota ;

Wloch, Jan ;

Lewinski, Andrzej .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) :26-35

[20] Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy [J].

Cabel, Luc ;

Proudhon, Charlotte ;

Romano, Emanuela ;

Girard, Nicolas ;

Lantz, Olivier ;

Stern, Marc-Henri ;

Pierga, Jean-Yves ;

Bidard, Francois-Clement .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (10) :639-650

← 1 2 3 4 5 6 7 8 9 10 →